92 related articles for article (PubMed ID: 16723555)
1. Novel conjugate of moxifloxacin and carboxymethylated glucan with enhanced activity against Mycobacterium tuberculosis.
Schwartz YS; Dushkin MI; Vavilin VA; Melnikova EV; Khoschenko OM; Kozlov VA; Agafonov AP; Alekseev AY; Rassadkin Y; Shestapalov AM; Azaev MS; Saraev DV; Filimonov PN; Kurunov Y; Svistelnik AV; Krasnov VA; Pathak A; Derrick SC; Reynolds RC; Morris S; Blinov VM
Antimicrob Agents Chemother; 2006 Jun; 50(6):1982-8. PubMed ID: 16723555
[TBL] [Abstract][Full Text] [Related]
2. [Study of antituberculous activity of moxifloxacin conjugate with macrophage scavenger-receptor ligand].
Azaev MSh; Agafonov AP; Bodnev SA; Blinov VM
Antibiot Khimioter; 2006; 51(11-12):7-10. PubMed ID: 18318141
[TBL] [Abstract][Full Text] [Related]
3. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
[TBL] [Abstract][Full Text] [Related]
4. Encapsulation of moxifloxacin within poly(butyl cyanoacrylate) nanoparticles enhances efficacy against intracellular Mycobacterium tuberculosis.
Kisich KO; Gelperina S; Higgins MP; Wilson S; Shipulo E; Oganesyan E; Heifets L
Int J Pharm; 2007 Dec; 345(1-2):154-62. PubMed ID: 17624699
[TBL] [Abstract][Full Text] [Related]
5. Limited-sampling strategies for therapeutic drug monitoring of moxifloxacin in patients with tuberculosis.
Pranger AD; Kosterink JG; van Altena R; Aarnoutse RE; van der Werf TS; Uges DR; Alffenaar JW
Ther Drug Monit; 2011 Jun; 33(3):350-4. PubMed ID: 21544017
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Shandil RK; Jayaram R; Kaur P; Gaonkar S; Suresh BL; Mahesh BN; Jayashree R; Nandi V; Bharath S; Balasubramanian V
Antimicrob Agents Chemother; 2007 Feb; 51(2):576-82. PubMed ID: 17145798
[TBL] [Abstract][Full Text] [Related]
7. Moxifloxacin population pharmacokinetics in patients with pulmonary tuberculosis and the effect of intermittent high-dose rifapentine.
Zvada SP; Denti P; Geldenhuys H; Meredith S; van As D; Hatherill M; Hanekom W; Wiesner L; Simonsson US; Jindani A; Harrison T; McIlleron HM
Antimicrob Agents Chemother; 2012 Aug; 56(8):4471-3. PubMed ID: 22585223
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug.
Jia L; Tomaszewski JE; Hanrahan C; Coward L; Noker P; Gorman G; Nikonenko B; Protopopova M
Br J Pharmacol; 2005 Jan; 144(1):80-7. PubMed ID: 15644871
[TBL] [Abstract][Full Text] [Related]
9. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
10. Novel, potent, orally bioavailable and selective mycobacterial ATP synthase inhibitors that demonstrated activity against both replicating and non-replicating M. tuberculosis.
Singh S; Roy KK; Khan SR; Kashyap VK; Sharma A; Jaiswal S; Sharma SK; Krishnan MY; Chaturvedi V; Lal J; Sinha S; Dasgupta A; Srivastava R; Saxena AK
Bioorg Med Chem; 2015 Feb; 23(4):742-52. PubMed ID: 25614114
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions.
Kjellsson MC; Via LE; Goh A; Weiner D; Low KM; Kern S; Pillai G; Barry CE; Dartois V
Antimicrob Agents Chemother; 2012 Jan; 56(1):446-57. PubMed ID: 21986820
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves.
Pathania R; Sharma SK
Res Vet Sci; 2010 Aug; 89(1):108-12. PubMed ID: 20202656
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of the newly synthesised ER-2 against clinical isolates of Mycobacterium tuberculosis susceptible or resistant to antituberculosis drugs.
Rao SS; Raghunathan R; Ekambaram R; Raghunathan M
Int J Antimicrob Agents; 2009 Nov; 34(5):451-3. PubMed ID: 19625168
[TBL] [Abstract][Full Text] [Related]
14. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
15. Moxifloxacin lethality against Mycobacterium tuberculosis in the presence and absence of chloramphenicol.
Malik M; Drlica K
Antimicrob Agents Chemother; 2006 Aug; 50(8):2842-4. PubMed ID: 16870782
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics, plasma protein binding and bioavailability of moxifloxacin in Muscovy ducks after different routes of administration.
Goudah A; Hasabelnaby S
Res Vet Sci; 2010 Jun; 88(3):507-11. PubMed ID: 20004428
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice.
Lounis N; Bentoucha A; Truffot-Pernot C; Ji B; O'Brien RJ; Vernon A; Roscigno G; Grosset J
Antimicrob Agents Chemother; 2001 Dec; 45(12):3482-6. PubMed ID: 11709328
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations.
Goudah A; Hasabelnaby S
Chemotherapy; 2010; 56(1):26-31. PubMed ID: 20197659
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and milk penetration of moxifloxacin after intramuscular administration to lactating goats.
Cárceles CM; Villamayor L; Escudero E; Marín P; Fernández-Varón E
Vet J; 2007 Mar; 173(2):452-5. PubMed ID: 16377219
[TBL] [Abstract][Full Text] [Related]
20. Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system.
Ginsburg AS; Lee J; Woolwine SC; Grosset JH; Hamzeh FM; Bishai WR
Antimicrob Agents Chemother; 2005 Feb; 49(2):853-6. PubMed ID: 15673788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
